keyword
MENU ▼
Read by QxMD icon Read
search

Multiple myeloma research

keyword
https://www.readbyqxmd.com/read/28737990/cost-effectiveness-of-novel-agents-in-medicare-patients-with-multiple-myeloma-findings-from-a-u-s-payer-s-perspective
#1
Ying Chen, David R Lairson, Wenyaw Chan, Jinhai Huo, Xianglin L Du
BACKGROUND: Since multiple myeloma (MM) incurs a substantial economic burden in care management, more and more discussion has been generated in recent years about the costs of novel antimyeloma drugs and their associated value. Because of these costs, economic assessment that quantifies value of care over the long-term is essential. OBJECTIVE: To determine the cost-effectiveness (measured as cost per life-year saved) of front-line novel agent-based therapy use among a cohort of elderly patients with MM in a real-world setting...
August 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28732370/silibinin-an-old-drug-for-hematological-disorders
#2
REVIEW
Hai Zou, Xing-Xing Zhu, Guo-Bing Zhang, Yuan Ma, Yi Wu, Dong-Sheng Huang
Silibinin (silybin), a non-toxic natural polyphenolic flavonoid, is the principal and the most biologically active component of silymarin. It is efficient in the treatment of acute and chronic liver disorders caused by toxins, drug, alcohol, hepatitis, and gall bladder disorders. Further, in our previous studies, we explored the anti-cancer efficacy in common cancers, such as lung, prostatic, colon, breast, bladder, as well as, hepatocellular carcinoma. Interestingly, silibinin is still not solely limited to the treatment of these diseases...
July 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28729122/evidence-based-guidelines-for-preventing-and-managing-side-effects-of-multiple-myeloma
#3
REVIEW
Page Bertolotti, Amy Pierre, Sandra Rome, Beth Faiman
OBJECTIVE: To review disease-related symptoms and side effects of treatment in patients with multiple myeloma (MM). DATA SOURCES: Peer-reviewed articles, research studies, and clinical guidelines. CONCLUSION: New therapies provide patients with extended survival, but in many cases this benefit is counterbalanced by an increased incidence of side effects. Preservation of organ function, while managing side effects, is essential for the care of patients with MM...
July 18, 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28729120/hematopoietic-stem-cell-transplantation-for-multiple-myeloma
#4
REVIEW
Heather L Koniarczyk, Christina Ferraro, Teresa Miceli
OBJECTIVE: To provide an overview of the hematopoietic stem cell transplantation (HSCT) process specific to patients with multiple myeloma (MM) and their caregivers. DATA SOURCES: Research studies, book chapters, websites, expert knowledge, and journal articles. CONCLUSION: Although not curative, autologous HSCT is an important, manageable treatment modality, and continues to be a standard of care in MM for those patients who are eligible...
July 17, 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28724539/racial-and-ethnic-disparities-in-hematologic-malignancies
#5
Kedar Kirtane, Stephanie J Lee
Racial and ethnic disparities in patients with solid malignancies have been well documented. Less is known about these disparities in patients with hematologic malignancies. With the advent of novel chemotherapeutics and targeted molecular, cellular, and immunologic therapies, it is important to identify differences in care that may lead to disparate outcomes. This review provides a critical appraisal of the empirical research on racial and ethnic disparities in incidence, survival, and outcomes in patients with hematologic malignancies...
July 19, 2017: Blood
https://www.readbyqxmd.com/read/28711372/patient-reported-outcomes-in-optimizing-myeloma-patients-health-related-quality-of-life
#6
REVIEW
Tracy A King, M T King, K J White
OBJECTIVE: To review the current state of evidence for the use of patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in optimizing best supportive care for patients with multiple myeloma (MM). DATA SOURCES: Peer-reviewed journal articles, research reports, state of the science papers, and clinical guidelines. CONCLUSION: The diagnosis and treatment of MM negatively impacts an individual's HRQoL. Validated self-report tools that assess HRQoL and other PROs provide an insight into how the treatment or disease is impacting the individual, enabling early recognition of physical and emotional concerns...
July 12, 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28707587/immunotherapeutic-interleukin-6-or-interleukin-6-receptor-blockade-in-cancer-challenges-and-opportunities
#7
Nirmala C Kampan, Sue D Xiang, Orla M McNally, Andrew N Stephens, Michael A Quinn, Magdalena Plebanski
Interleukin 6 (IL-6), a well-known pro-inflammatory cytokine with pleiotropic activity is a central player in chronic inflammatory diseases including cancers. Therefore, blockade of the IL-6 signaling pathway has become a target for the therapy of in diverse cancers such as multicentric Castleman's disease (CD), multiple myeloma and solid tumours including renal, prostate, lung, colorectal and ovarian cancers. Monoclonal antibodies against IL-6 (Siltuximab) and the IL-6 receptor (IL-6R) (Tocilizumab) have emerged as potential immunotherapies, alone or in combination with conventional chemotherapy...
July 12, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28683956/strategies-for-selecting-the-optimal-treatment-in-newly-diagnosed-multiple-myeloma-patients
#8
REVIEW
Mary Steinbach, Tiffany Richards, Beth Faiman
OBJECTIVE: To review the current evidence on strategies for selecting the optimal treatment for newly diagnosed patients with multiple myeloma (MM). DATA SOURCES: Journal articles, research reports, state of the science papers, and clinical practice guidelines. CONCLUSION: Despite the plethora of drugs to effectively treat MM, the optimal induction regimen for patients with newly diagnosed MM is unknown. Rapid control of the disease, appropriate treatment selection and effective supportive care strategies remain integral to prevention and management of the disease...
July 3, 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28678757/the-therapeutic-potential-of-cell-cycle-targeting-in-multiple-myeloma
#9
REVIEW
Anke Maes, Eline Menu, Kim De Veirman, Ken Maes, Karin Vanderkerken, Elke De Bruyne
Proper cell cycle progression through the interphase and mitosis is regulated by coordinated activation of important cell cycle proteins (including cyclin-dependent kinases and mitotic kinases) and several checkpoint pathways. Aberrant activity of these cell cycle proteins and checkpoint pathways results in deregulation of cell cycle progression, which is one of the key hallmarks of cancer. Consequently, intensive research on targeting these cell cycle regulatory proteins identified several candidate small molecule inhibitors that are able to induce cell cycle arrest and even apoptosis in cancer cells...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28677774/construction-of-a-recombinant-lentivirus-mediated-shrna-expression-vector-targeting-the-human-psmd10-gene-and-validation-of-rnai-efficiency-in-rpmi%C3%A2-8226-multiple-myeloma-cells
#10
Siyue Du, Wenjiao Qin, Haiyan Leng, Zi Chen, Tao Zhang
Multiple myeloma (MM) is one of the most common malignant blood cancers. Previous studies have reported that proteasome 26S subunit non-ATPase 10 (PSMD10) is an oncoprotein with complex roles in hepatocellular carcinoma and other malignant tumors. Notably, research on the relationship between PSMD10 and tumorigenesis of MM has rarely been reported. The present study was designed to explore the possibility of PSMD10 as a therapeutic target in the treatment of MM, and the use of RNA interference (RNAi) to determine the function PSMD10...
June 30, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28666621/immunomodulatory-agents-and-proteasome-inhibitors-in-the-treatment-of-multiple-myeloma
#11
REVIEW
Kimberly Noonan, Kathleen Colson
OBJECTIVE: To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). DATA SOURCES: Journal articles, research reports, state of the science papers, and clinical guidelines. CONCLUSION: There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens...
June 27, 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28645097/raman-spectroscopy-differentiates-between-sensitive-and-resistant-multiple-myeloma-cell-lines
#12
Domenico Franco, Sebastiano Trusso, Enza Fazio, Alessandro Allegra, Caterina Musolino, Antonio Speciale, Francesco Cimino, Antonella Saija, Fortunato Neri, Marco S Nicolò, Salvatore P P Guglielmino
Current methods for identifying neoplastic cells and discerning them from their normal counterparts are often nonspecific and biologically perturbing. Here, we show that single-cell micro-Raman spectroscopy can be used to discriminate between resistant and sensitive multiple myeloma cell lines based on their highly reproducible biomolecular spectral signatures. In order to demonstrate robustness of the proposed approach, we used two different cell lines of multiple myeloma, namely MM.1S and U266B1, and their counterparts MM...
June 15, 2017: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://www.readbyqxmd.com/read/28626849/equal-treatment-and-outcomes-for-everyone-with-multiple-myeloma-are-we-there-yet
#13
REVIEW
Sikander Ailawadhi, Kirtipal Bhatia, Sonikpreet Aulakh, Zahara Meghji, Asher Chanan-Khan
Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics...
June 19, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28620928/the-importance-of-the-number-of-transplanted-cells-with-dipeptidyl-peptidase-4-expression-on-the-haematopoietic-recovery-and-lymphocyte-reconstitution-in-patients-with-multiple-myeloma-after-autologous-haematopoietic-stem-cell-transplantation
#14
Anna Kopinska, Małgorzata Krawczyk-Kulis, Joanna Dziaczkowska-Suszek, Katarzyna Bieszczad, Krystyna Jagoda, Slawomira Kyrcz-Krzemien
Autologous haematopoietic stem cell transplantation (AHSCT) remains recommended treatment in the first remission in multiple myeloma (MM). In earlier research it has been suggested that there is an influence of the expression of dipeptidyl peptidase-4 (CD26) on both the homing and lymphocyte reconstitution after AHSCT. The aim of the study is to investigate the influence of transplanted cells CD26+ on the haematopoietic recovery and lymphocyte reconstitution after AHSCT in MM. Forty eight patients with MM underwent AHSCT in our centre...
June 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28610537/overcoming-multiple-myeloma-drug-resistance-in-the-era-of-cancer-omics
#15
Matthew Ho Zhi Guang, Amanda McCann, Giada Bianchi, Li Zhang, Paul Dowling, Despina Bazou, Peter O'Gorman, Kenneth C Anderson
Multiple myeloma (MM) is among the most compelling examples of cancer in which research has markedly improved the length and quality of lives of those afflicted. Research efforts have led to 18 newly approved treatments over the last 12 years, including seven in 2015. However, despite significant improvement in overall survival, MM remains incurable as most patients inevitably, yet unpredictably, develop refractory disease. Recent advances in high-throughput 'omics' techniques afford us an unprecedented opportunity to (1) understand drug resistance at the genomic, transcriptomic, and proteomic level; (2) discover novel diagnostic, prognostic, and therapeutic biomarkers; (3) develop novel therapeutic targets and rational drug combinations; and (4) optimize risk-adapted strategies to circumvent drug resistance, thus bringing us closer to a cure for MM...
June 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28599191/targeting-autophagy-in-multiple-myeloma
#16
REVIEW
Zhuang Yun, Jin Zhichao, Yao Hao, Ji Ou, Yang Ran, Dong Wen, Shen Qun
Autophagy plays an important role in plasma cell ontogeny and in the pathophysiology of multiple myeloma. Autophagy is usually considered a pro-survival mechanism, and cooperates with the ubiquitin proteasome system in maintaining the homeostasis of myeloma cells by degrading excessive and misfolded proteins for energy recycling. Therefore, the inhibition of autophagy could effectively induce death in myeloma cells, and could synergize with proteasome inhibitors. However, the excessive activation of autophagy could also lead to the extreme degradation of the organelles that induce autophagic cell death...
June 3, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28592764/multiple-myeloma-pathophysiology-and-progress-in-management
#17
Junya Kuroda, Yoshiaki Chinen
There have been dramatic recent advances in understanding the basic pathophysiology and treatment strategies for multiple myeloma (MM). Research has shown both a high inter-patient diversity and intra-clonal heterogeneity even in a single patient in terms of cytogenetic/molecular abnormalities, and has also identified marked diversity in the immunological factors involved in tumor surveillance among MM patients. In the presence of a variety of novel agents, including molecular-targeted agents, immunomodulatory agents, and monoclonal antibodies, the optimal translation of current knowledge on both molecular and immunologic findings into clinical use is crucial for managing MM...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28581468/a-phase-i-ii-minor-histocompatibility-antigen-loaded-dendritic-cell-vaccination-trial-to-safely-improve-the-efficacy-of-donor-lymphocyte-infusions-in-myeloma
#18
L E Franssen, M W H Roeven, W Hobo, R Doorn, R Oostvogels, J H F Falkenburg, N W van de Donk, M G D Kester, H Fredrix, K Westinga, I Slaper-Cortenbach, E Spierings, M J Kersten, H Dolstra, T Mutis, N Schaap, H M Lokhorst
Allogeneic stem cell transplantation (allo-SCT) with or without donor lymphocyte infusions (DLI) is the only curative option for several hematological malignancies. Unfortunately, allo-SCT is often associated with GvHD, and patients often relapse. We therefore aim to improve the graft-versus-tumor effect, without increasing the risk of GvHD, by targeting hematopoietic lineage-restricted and tumor-associated minor histocompatibility antigens using peptide-loaded dendritic cell (DC) vaccinations. In the present multicenter study, we report the feasibility, safety and efficacy of this concept...
June 5, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28573439/using-pharmacy-management-systems-for-research-survival-outcomes-for-lenalidomide-in-multiple-myeloma-in-the-clinical-setting
#19
Megan M Sharkey, Daniel McKavanagh, Euan Walpole, Peter Mollee, Samantha A Hollingworth
Background Health records can be used to measure medicine use and health outcomes. The public subsidy of lenalidomide in Australia was based on two phase III trials showing improved survival. Objective To use hospital pharmacy information management systems to determine survival outcomes for lenalidomide as a second line treatment in relapsed or refractory multiple myeloma (RRMM) patients. Setting Five public hospitals in Queensland, Australia. Method We extracted data on medicine use and survival for RRMM patients planned to start lenalidomide from pharmacy management and pathology databases...
June 1, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/28557972/high-expression-of-phosphorylated-extracellular-signal-regulated-kinase-erk1-2-is-associated-with-poor-prognosis-in-newly-diagnosed-patients-with-multiple-myeloma
#20
Liping Fan, Jinquan Hong, Haobo Huang, Danhui Fu, Shunquan Wu, Qingqing Wang, Yamei Ye, Yun Liu
BACKGROUND Previous research has demonstrated that the extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway is commonly activated in multiple myeloma (MM) patients. However, the prognostic value of activation of the MEK/ERK signaling pathway in newly diagnosed patients with MM has not been reported. MATERIAL AND METHODS Expression levels of p-ERK1/2 protein in bone marrow biopsy specimens obtained from 60 newly diagnosed patients with MM were analyzed using immunohistochemistry, and classified into 3 groups: high p-ERK1/2 expression, low p-ERK1/2 expression, and negative group...
May 30, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
keyword
keyword
105424
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"